SK Biopharma Partners With Insilico Medicine on $2.5B AI Drug Deal

According to Cailianshe, on June 22, SK Biopharmaceuticals and Insilico Medicine announced a collaboration on drug discovery for neuroimmune diseases at the BIO convention. Insilico will receive up to $18 million in upfront and near-term milestone payments, with the total deal value reaching over $2.5 billion including development, regulatory, and commercialization milestones, plus single-digit royalties on net sales. Insilico will conduct discovery through its Pharma.AI platform, while SK Biopharmaceuticals leads development and commercialization. Insilico Medicine's Hong Kong-listed shares rose over 13% following the announcement.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments